MENU
+Compare
GDOC
ETF ticker: NYSE ARCA
AS OF
Jan 17 closing price
Price
$32.80
Change
-$0.19 (-0.58%)
Net Assets
20.62M

GDOC stock forecast, quote, news & analysis

Category: @Health
GDOC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for GDOC with price predictions
Jan 08, 2025

GDOC in +1.64% Uptrend, rising for three consecutive days on January 07, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GDOC advanced for three days, in of 193 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GDOC's RSI Oscillator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 06, 2025. You may want to consider a long position or call options on GDOC as a result. In of 56 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GDOC just turned positive on January 06, 2025. Looking at past instances where GDOC's MACD turned positive, the stock continued to rise in of 29 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GDOC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for GDOC entered a downward trend on January 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Intuitive Surgical (NASDAQ:ISRG), Bristol-Myers Squibb Co (NYSE:BMY), Boston Scientific Corp (NYSE:BSX), ZOETIS (NYSE:ZTS), Edwards Lifesciences Corp (NYSE:EW), Humana (NYSE:HUM), Biogen (NASDAQ:BIIB).

Industry description

The investment seeks long-term growth of capital. The fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) in equity investments in U.S. and non‑U.S. health care companies. The adviser generally intends to invest in companies that the adviser believes are aligned with key themes associated with innovation in health care, which include, but are not limited to, genomics, precision medicine, technology-enabled procedures, and digital healthcare. The fund is non-diversified.

Market Cap

The average market capitalization across the Goldman Sachs Future Health Care Eq ETF ETF is 59.6B. The market cap for tickers in the group ranges from 1.44B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is DYN at 1.44B.

High and low price notable news

The average weekly price growth across all stocks in the Goldman Sachs Future Health Care Eq ETF ETF was 0%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was -7%. ITCI experienced the highest price growth at 33%, while DYN experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Goldman Sachs Future Health Care Eq ETF ETF was 1%. For the same stocks of the ETF, the average monthly volume growth was 1% and the average quarterly volume growth was 34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 73
Price Growth Rating: 55
SMR Rating: 63
Profit Risk Rating: 63
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
GDOC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Goldman Sachs ETF Trust200 West StreetNew York
Phone
N/A
Web
N/A